
# **Plex**PCR<sup>®</sup> VHS

Varicella, Herpes and Syphilis

## Confident lesion testing to suit any population



## Syphilis rates are on the rise<sup>1-8</sup>

- Symptomatic/visual lesion diagnostics can have low accuracy (33-80%),<sup>9-11</sup> molecular testing is recommended<sup>12-15,17-18</sup>
- Syphilis lesions can present atypically, be painful, and appear indistinguishable from herpes<sup>13,19,20</sup>
- Atypical zoster (VZV) may account for 1-3%<sup>21-23</sup> of genital lesions, misdiagnosis can affect patient psychological wellbeing



### C€ IVD ĽK IVDR Certified

One kit. Two tests.	SpeeDx Software Module	Targets
Individual software modules provide two tests for one validation/verification. The	PlexPCR <sup>®</sup> HV (7500) PlexPCR <sup>®</sup> HV (LC480) PlexPCR <sup>®</sup> HV (CFX)	HSV-1 / HSV-2 / VZV
automated analysis is included with the <b>Plex</b> PCR <sup>®</sup> VHS lesion diagnostics solution.	PlexPCR® VHS (7500 PlexPCR® VHS (LC480) PlexPCR® VHS (CFX)	HSV-1 / HSV-2 / VZV / T. pallidum

- Suitable for high or low risk population testing
- Multiple analysis module options for flexible target analysis
- Choose all four targets or herpes and varicella only
- Modules analysed simulatenously to streamline workflow and data analysis

## Fast and reproducible data analysis.


## Streamline your workflow and minimise time spent with subjective amplification curves with SpeeDx Analysis software.

The complete **Plex**PCR<sup>®</sup> VHS solution includes:

- Automated result calling
- Simple sample processing
- Validated, high security, GDPR compliance
- Multiple analysis modules with or without syphilis

					DATA INPUTS RESULTS	EXPORTS REPORTS	REPORT VIEWER
DATA BRATS RESULTS DP	ORTS REPORTS REPORT VEWER				Results overview Resolve Details		
Select datafile Assign assay(s)	3 Configure assay(s)				Table filters 🛛 Results		Amplification curves 🛛 🗖 🖗 🔍
Plate  Table	All () Assigned Secret Q, She	aing 7 of 7					3,911,752.55
A 3 3 4 5 6 7 8 9 10 11 12 A 3 4 5 6 7 8 9 10 11 12	Show all assays on plate				Res Well Sample	Assay Cq values	3,411,752.55 8 2,911,752.55
	PeaPCR VHS (7500) - v0.14 (SpeeDa)	-			• • • • • • • • • • • • • • • • • • •	PlexPCR VHS (7500) - Pl (7500) - Pl	0 2911/15255 2,411,752.55
	PROPERTYPE 🕚 🕓 🕑 🚱 🚱 🕼					HSV-1: 17.45	8 1911.752.55 1411.752.55
	PlexPCR VHS (7500) - v0.17 (SpeeDx)					IC: 24.20	911,752.55 -
	PlexPCR VHS 🗿 🕓 🕑 😰 🕜					T. pallidum: 24.00	411,752.55 10 20 30 40
0000000000000	ResistancePlus MG (7500 Dx) - v0.1 (SpeeDx)						Cycle
	MG 🕓 🙆 🌔 Name	Assay	Result	Cq values	Overall results		
	ResistancePlus M0 403	PlexPCR VHS (7500) - PlexPCR VHS	Positive	JOE: 19.30 TAMRA: 26.35	403 HSV-1 detected		Baseline-corrected ampl P R O Q
Select all Deselect all Onar selected Detect assays	MS (S) (S)	PlexPCR VHS (7500) - PlexPCR VHS	Positive	FAM: 13.80 TAMRA: 26.05 CyS: 36.35	356 T. pallidum, HSV-2 detected		1,933,998.66
PREVALUS STEP	419	PiexPCR VHS (7500) - PiexPCR VHS	Negative	TAMRA: 25.25	419 Negative. IC valid.		5 933,998,66 433,998,66 -66,001,34 10 20 30 40
	1047	PlexPCR VHS (7500) - PlexPCR VHS	Positive	Texas Red: 15.00 TAMRA: 26.65	1047 VZV detected		Cycle
	1048	PlexPCR VHS (7500) - PlexPCR VHS	Negative	TAMRA: 27.45	1048 Negative, IC valid.	1	
	1051	PlexPCR VHS (7500) - PlexPCR VHS	Invalid	TAMRA: 29.70	1051 IC invalid. Re-extract and re-test sample.		
					to invente receivant and receiv animate.	1	

"We strongly believe in having a T. pallidum PCR as part of the routine test for any genito-anal ulcer. Several patients have been found to have syphilis where this was not originally suspected, and blood tests would never have been taken." Dr. Andrew Winter, Consultant in Sexual Health and HIV Medicine, NHS Greater Glasgow and Clyde, UK.






Molecular testing from a syphilis lesion is a direct detection method—simplifying diagnosis and enabling timely partner notification and contact tracing<sup>27</sup>



Surveillance or sentinal lesion screening can assist with early detection<sup>28,29</sup> Syphilis clusters increasingly include heterosexual populations,<sup>24,25</sup> coinciding with increases in congenital syphilis<sup>26</sup>



Atypical lesion presentation can complicate diagnosis<sup>13,19-23</sup>



Syphilis at highest rates in decades, including rise in congenital syphilis cases<sup>1-3,9,16</sup>

Increased number of reported syphilis epidemics and outbreaks<sup>30-32</sup>



PlexPCR<sup>®</sup> VHS is a single-well, mulitplex qPCR test detecting common causes of genital and oral lesions. Detect Herpes simplex virus type-1 and -2 (HSV-1 and HSV-2), and Varicella zoster virus (VZV), with software analysis options to include Treponema pallidum (syphilis) detection. PlexPCR<sup>®</sup> VHS is powered by **Plex**PCR<sup>®</sup> proprietary technologies for improved multiplex performance compared with other probe-based methods.<sup>33</sup>

#### Single-well PlexPCR® Test

Channel	Target	
1	HSV-1	
2	HSV-2	
3	VZV	
4	T. pallidum (optional analysis)	
5	Internal Control	

#### Demonstrated clinical performance<sup>34</sup>

	HSV-1	HSV-2	VZV	TP
Sensitivity	97.7%	100%	100%	100%
Specificity	99.7%	99.7%	99.7%	100%

Validated with non-genital and genital swabs, genital, non-genital, anal/ rectal and oral swab specimens.

# **Plex**PCR<sup>®</sup> VHS

## Flexible lesion diagnostics

Product	Compatible	Size	Cat #
<b>Plex</b> PCR <sup>®</sup> VHS*	ABI 7500/7500 Fast/Dx	100 reactions	1123001
	LC480 II	100 reactions	1121001
	CFX IVD, CFX Touch	100 reactions	1125001

\*CE-IVD, TGA cleared. Not for sale in the US

References: 1. Australian Institute of Health and Welfare 2018. Australia's health 2018. Australia's health series no. 16. 2. ECDC surveillance atlas of infectious diseases, syphilis 2015 3. CDC Sexually Transmitted Disease Surveillance 2017 4. Sexually Transmitted Infections. [S.L.]: National Academies Press; 2021. 5. National Overview - Sexually Transmitted Disease Surveillance, 2020 [Internet], Cdc.aov, 2021 [cited 2 August 2021], Available from: https://www.cdc.aov/std/statistics/2020/overview.htm 6. Prochazka M. et al. Tracking the syphilis epidemic in England; 2010 to 2019. January 2021, Public Health England, London. 7. National syphilis surveillance quarterly report - July to September 2022 [Internet] https://www.health.gov.au/resources/publications/ national-syphilis-surveillance-quarterly-report-july-to-september-2022?language=en [Cited 8 March 2023] Available from: https://www.health.gov.au/sites/default/files/2023-03/national-syphilissurveillance-quarterly-report-july-to-september-2022,pdf 8. European Centre for Disease Prevention and Control. . (n.d.). (tech.). Syphilis Annual Epidemiological Report for 2018. Retrieved from https://www.ecdc.europa.eu/sites/default/files/documents/syphilis-aer-2018.pdf 9. Dangor Y et al. Sex Transm Dis 1990; 17:184–189. 10. O'Farrell N et al. Genitourin Med 1994; 70: 7–11 11. Ndinya-Achola JO et al. Int J STD & AIDS 1996; 7: 201-205 12. Workowski KA et al MMWR Recomm Rep 2015;64 (RR03); 25-48 13. Janier M et al. 2020 European guideline on the management of syphilis https://onlinelibrary.wiley.com/doi/10.1111/jdv.16946 14. Australian STI Management Guidelines 2023 [Internet] https://sti.guidelines.org.au/ [cited 8 March 2023] Available from https://sti.guidelines.org.au/sexually-transmissible-infections/syphilis/ 15. Patel R et al. 2017 European guidelines for the management of genital herpes 16. Abara WE et al. PLOS ONE Published online 22 July 2016 17. Kingston M et al. UK national guidelines on the management of syphilis 2015 18. Grange et al 2021: Use of a Multiplex PCR Assay To Assess the Presence of Treponema pallidum in Mucocutaneous Ulcerations in Patients with Suspected Syphilis Print 2021 Jan 21 [Internet] https://pubmed.ncbi.nlm.nih.gov/33177120/ [Cited 15 March 2023] 19.Towns JM Sex Transm Infect. 2016 Mar;92(2):110-5 20. Hope-Rapp E et al. J Sex Transm Dis. 2010;37:153-8 21. Rübben A et al. Br J Dermatol. 1997;137(2):259-61 22. Granato PA et al. J Clin Virol. 2016 Nov:84:87-89 23. Birch C et al. Sex Transm Infect. 2003; 79:298-300 24. Cunningham S et al. Sex Transm Infect. 2006;82:444-445 25. Doherty IA et al. Sex Transm Dis. 2011 May; 38(5): 378-384 26. Slutsker JS et al. MMWR Morb Mortal Wkly Rep 2018;67:1088–1093 27. Goldstein et al. 2021 Diagn Microbiol Infect Dis. 2021 Feb;99(2):115221.doi: 10.1016/j.diagmicrobio.2020.115221. Epub 2020 Sep 21. https://pubmed.ncbi.nlm.nih.gov/33176262/ 28. Syphilis CDNA National Guidelines for Public Health Units v1.1, June 2018 29. Scott LJ Sex Transm Infect 2010 86:537-539 30. Victoria Government Department Health [Internet]. https://www.health.vic.gov.au/ [cited 4 March 2023] https://www.health.vic.gov.au/infectious-diseases/local-government-areas-surveillancereport 31. Bright A & Dups J, Communicable Diseases Intelligence Volume 40 No 1 - March 2016 32. Arizona Dept. Health & Services, Real-Time Syphilis Data 2018 33. Mokany E., Tan Y.L., Bone S.M., Fuery C., Todd A.V., 2013. MNAzyme qPCR with superior multiplexing capacity. Clin. Chem. 59(2); 419-426 34. PlexPCR<sup>®</sup> VHS Instructions for use

PlexPCR® VHS kits are developed and manufactured by SpeeDx Pty Ltd, Sydney. PlexPCR® & SpeeDx® are registered trademarks of SpeeDx Pty Ltd. Other copyright and trademarks are the property of the respective owners. SpeeDx Pty Ltd products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/patents for comprehensive patent information.

#### Australia - SpeeDx Pty. Ltd. +61 (0)2 9209 4170 sales@speedx.com.au

Suite 102, 4 Cornwallis Street, Eveleigh NSW 2015 Australia

#### Europe - SpeeDx Ltd. +44 (0)330 445 0036 sales.uk@speedx.com.au Acre House 11/15 William Road

London NW1 3ER United Kingdom



### Find out more plexpcr.com